RJRoni M. Jacobsen

Roni M. Jacobsen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Roni M. Jacobsen has a total of 200 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • The Fontan Outcomes Network: Findings After 2 Years and 1121 Participants

    by Thomas M. Glenn, Nadine A. Kasparian, Shahnawaz Amdani, David Renaud, Michael V. DiMaria, Jennifer Teh, David M. Leone, Arjun K. Mahendran, Nancy A. Pike, Stephen J. Dolgner, et al.

    BACKGROUND: Survival after Fontan palliation for single ventricle heart disease has improved substantially, yet the long-term trajectory remains poorly defined. The Fontan Outcomes Network, a learning health network of 38 congenital heart centers in the United States and Canada, was established to address this gap. We report baseline characteristics and early findings from the first 1121 participants enrolled in this prospective clinical registry. METHODS: We performed a cross-sectional analysis of individuals who had undergone Fontan palliation enrolled in the Fontan Outcomes Network from August 2022 through August 2024. Demographic, clinical, imaging, procedural, and medication data were analyzed descriptively, overall and by age group (<12, 12 to <18, and ≥18 years). RESULTS: A total of 1121 participants were enrolled (mean age, 16.3±10.2 years; 471 [42%] female). Hypoplastic left heart syndrome (n=431 [38.5%]) and right ventricular–dominant anatomy (n=615 [54.9%]) were the most common primary cardiac diagnoses, especially in younger age groups. Extracardiac conduit was the most frequent Fontan type (n=749 [66.8%]). Typical Fontan-related adverse events were noted in 59% of cases (n=662), including chylous pleural effusions (n=108 [9.6%]), Fontan thrombosis (n=79 [7.1%]), and nonperioperative stroke (n=73 [6.5%]). A history of arrhythmia was present in 41.3% of patients (n=463) overall, increasing with age. Acquired comorbidities were present in 57.5% of patients (n=645), including asthma (n=132 [12%]) and sleep apnea (n=103 [9%]), with burden increasing by age. Antithrombotic medication use was nearly universal. Use of other medications varied widely by age, and included β-blockers, angiotensin-converting enzyme inhibitors, and pulmonary vasodilators. A clinical diagnosis of an anxiety disorder was present in 34.1% of patients (n=382), including 48.1% of adults (n=194 of 403), and antidepressants were prescribed in 11.8% of patients (n=132), including 23.6% of adults (n=95 of 403), highlighting the mental health needs of this population. CONCLUSIONS: The Fontan Outcomes Network includes one of the largest prospective, multi-institutional data sets of patients with Fontan circulation. These initial findings demonstrate the potential for a collaborative learning health network to advance research and quality improvement for this rare disease population.


  • Open Access

    Fontan Subtype, Conduit Size, and Cardiac Morphologic Factors and Their Relationship to Exercise Capacity in the Fontan Circulation: A Single Ventricle Outcomes Network (SV-ONE) Study

    by David Michael Leone, SV-ONE Investigators, Thomas M Glenn, Imran Ross Masood, Arash A. Sabati, David Alexander White, Jared Hershenson, Michael J Danduran, Katherine Helen Hansen, Michael Khoury, et al.

    Background: Exercise capacity varies among individuals with a Fontan circulation. Percent predicted peak oxygen consumption (%pVO 2 ) may be influenced by ventricular morphology, Fontan subtype, and conduit characteristics, but data explaining variability in exercise capacity are limited. This study examined whether anatomical and surgical factors are associated with %pVO 2 later in life. Methods: Participants enrolled in the multicenter Single Ventricle Outcomes Network (SV-ONE) database who had cardiopulmonary exercise testing (CPET) data were included. Published reference equations were used to estimate %pVO 2 . Multivariable regression models evaluated associations between anthropometric, anatomical (diagnosis and dominant ventricle), and surgical (Fontan subtype, conduit size, and surgical era) factors and %pVO 2 . Restricted spline analyses assessed nonlinearity. Results: 561 individuals with a Fontan circulation were included in the analysis; age 20 ± 8 years, 54% male, mean %pVO 2 was 63 ± 16%. Sex and exercise modality were the strongest predictors of %pVO 2 , with females being 12% higher than males and treadmill 4.6% higher than a cycle. Age at CPET was a predictor of exercise capacity with %pVO 2 decreasing by 0.8% per year. Ventricular morphology, diagnosis, and Fontan subtype did not have a statistical association with the primary outcome. In models restricted to patients with an extracardiac conduit (n = 330), conduit diameter and area were not associated with %pVO 2 , even after indexing to body surface area. Univariable nonlinear spline analyses suggested an optimal conduit size of 18 mm for %pVO 2 , but this was not significant after body size adjustments. Conclusion: In this large multicenter cohort, surgical and anatomical features were not as important as sex, age, and body size as determinants of exercise performance in patients with a Fontan circulation. Reduced exercise capacity in this population appears to reflect progressive pathophysiological changes of the Fontan circulation rather than specific characteristics such as conduit size, ventricular morphology, or anatomy. CLINICAL PERSPECTIVE: What is new?: In this large multicenter registry study of 561 patients with a Fontan circulation, we evaluated whether early surgical and anatomical factors, including dominant ventricular morphology, underlying diagnosis, Fontan subtype, and extracardiac conduit size, are associated with exercise performance later in life as measured by percent predicted peak VO 2 . These surgical and anatomical variables explained little of the variability in exercise capacity. In contrast, demographic and testing-related factors, particularly sex, along with age and body size, were much more strongly associated with percent predicted peak VO 2 . What are the clinical implications?: Despite longstanding interest in whether Fontan configuration or dominant ventricular morphology confers superior long-term exercise capacity, this study demonstrates that these surgical and anatomical factors contribute little to exercise performance later in life. For patients with a Fontan circulation, reduced exercise capacity should not be attributed primarily to Fontan subtype or conduit size. Instead, clinical care should emphasize modifiable contributors, including regular exercise participation, preservation of skeletal muscle mass, and proactive identification and management of hemodynamic abnormalities as they evolve over time.

  • Open Access

    The CHI-RON Study

    by Anitha S. John, Scott Leezer, Lindsey Rudov, Jamie L. Jackson, Mindi Messmer, Sneha Saraf, Rittal Mehta, Shreya Papneja, Arwa S. Saidi, Aliza Marlin, et al.

    Background: The Congenital Heart Initiative-Redefining Outcomes and Navigation to Adult-Centered Care (CHI-RON) study is a unique collaboration between the PCORnet and Congenital Heart Initiative (CHI), the first patient powered registry for adult congenital heart disease (ACHD) patients. The CHI-RON study examines the effects of gaps in recommended care in ACHD. Objective: Recruitment of racially diverse, younger, out-of-care, and male participants has been challenging in ACHD studies. Our goal was to design patient engagement and recruitment strategies to improve representation. Research Design: Launched in December 2020, patients from any location can self-enroll in the CHI registry, while the CHI-RON study (5/2022 – 10/2023) recruited ACHD patients at 12 sites participating in PCORnet. CHI-RON Recruitment methodology included a patient partner engagement toolkit and a recruitment algorithm using the PCORnet ® Common Data Model designed specifically to improve diversity and reduce self-enrollment biases in comparison to the CHI registry. Subjects: ACHD patients, age 18 years or older, with the ability to complete PROs independently. Measures: Demographic/Recruitment Statistics for study participants and Patient Engagement in Research Scale (PEIRS-22) for the study team partners. Results: As of October 2023, a total of 2652 participants were recruited through CHI-RON recruitment methodology while 1326 were self-enrolled in the CHI. CHI-RON recruitment methodologies have increased representation when compared with self-enrolled CHI participants in terms of ethnicity (10.9% vs. 7.4% Hispanic, P P P P P <0.001). Most study team patient partners (n=12, 86%) reported a very to extremely high degree of engagement (PEIRS-22 average score 101.6), especially in the subdomains of contributions, support, feeling valued, and benefits. Conclusions: Patient engagement and novel recruitment strategies are critical to improving the inclusion of under-represented populations in clinical research and ensuring alignment with the needs of ACHD patients.


  • Open Access

    Cardiopulmonary Exercise Testing is Safe in Children and Adolescents with Cardiomyopathy

    by Kelsey Iguidbashian, Julie Fernie, Kaitlin Olson, Jean Cavanaugh, Shelley D. Miyamoto, Roni Jacobsen

    Background: Cardiopulmonary exercise testing (CPET) has been recommended in pediatric patients with hypertrophic cardiomyopathy (HCM); however, safety has not been well defined. Studies in adults with cardiomyopathy (CM) consistently show reduced maximal and submaximal exercise capacity and impaired ventilatory efficiency compared to matched controls, with mixed data in children. This single-center retrospective study aimed to identify differences in adverse events and exercise parameters in children and adolescents with CM versus matched controls. Methods: From 2014 to 2023, 227 CPETs were completed in 141 patients with CM, ages 6 to 22 years. Only maximal CPETs were included for control-matched sub analysis, resulting in 113 tests in 83 CM patients. Subjects were matched with healthy controls based on sex, age, body mass index (BMI), body surface area (BSA), and stress exercise modality to evaluate for differences in heart rate (HR), systolic blood pressure (SBP), electrocardiogram (ECG) changes, incidence of adverse events (ischemia, SBP drop, and arrhythmias), exercise-induced symptoms, and peak exercise parameters. Results: There were 4 CM tests (all HCM, 1.8%) terminated due to adverse events: SBP drop (2) and non-sustained ventricular tachycardia (2). Control patients reported significantly more symptoms of chest pain and dizziness with exercise. Maximal and submaximal oxygen consumption (VO 2 ), SBP, HR, and minute ventilation (VE) were lower in CM patients. Conclusion: In our cohort, CPET testing in children and adolescents with CM was safe. Maximal and submaximal exercise capacity was reduced in CM patients, likely due to reduced cardiac output, with lower HR and VE at peak exercise. Future studies may identify if exercise parameters can be used to risk stratify patients or predict outcomes.

  • Open Access

    Methylated Arginine Metabolites as Biomarkers for Clinical Status and Response to Type 5 Phosphodiesterase Inhibition in Patients With Fontan Circulation

    by Ari Cedars, Cedric Manlhiot, Bhargava Kumar Chinni, Alexander R. Opotowsky, Kristian Becker, Anne Le, Pratik Khare, Jong Love Ko, Allen Everett, Shelby Kutty, et al.

    Background: There is significant interest in NO pathway modulators, specifically type 5 phosphodiesterase inhibitors (PDE5is), to treat patients with a Fontan circulation. Trials, however, have had mixed results. The relationship between the NO pathway and clinical status in patients with Fontan circulation is a significant knowledge gap. Methods and Results: We performed targeted metabolomic analysis using liquid chromatography coupled to mass spectrometry to quantify plasma NO pathway metabolite concentrations from 2 well‐characterized populations of patients with Fontan circulation: the Boston Adult Congenital Heart Disease Biobank and Fontan Udenafil Exercise Longitudinal studies. We investigated associations between NO metabolite concentrations and clinical outcomes, exercise capacity, and response to PDE5is. Increased plasma concentration of asymmetric dimethyl arginine (ADMA), an inhibitor of NO production, was associated with risk for hospitalization or death. Increased ADMA and symmetric dimethyl arginine (another inhibitor of NO production) concentrations were associated with decreased baseline exercise capacity among patients with Fontan circulation with <90% predicted peak oxygen uptake, and change in ADMA and symmetric dimethyl arginine concentrations were predictive of change in exercise capacity over time. Treatment with the PDE5i udenafil uncoupled this association. Finally, baseline ADMA and symmetric dimethyl arginine concentrations predicted response to PDE5is among patients with subnormal peak oxygen uptake. Conclusions: Plasma concentrations of metabolites that inhibit NO flux are associated with negative clinical outcomes and worse exercise capacity. Moreover, metabolite shifts over time associated with increased NO flux are associated with improved exercise capacity. In patients with a Fontan circulation, the NO pathway modulators ADMA and symmetric dimethyl arginine may be useful as biomarkers of clinical status and predictive of response to PDE5is.


  • Open Access

    The Congenital Heart Initiative: Results from a Patient-Centered Registry for Adults with Congenital Heart Disease

    by Scott Leezer, Mindi Messmer, Anushree Agarwal, Ruth Phillippi, Jamie L. Jackson, Mark Roeder, Aliza Marlin, Noah Peyser, Mark J. Pletcher, Richard Krasuski, et al.

    Background: In the United States, there are over 1.5 million adults living with congenital heart disease (CHD). The Congenital Heart Initiative (CHI) is a digital, online patient empowered registry that was created to advance multicenter research and improve clinical care by gathering patient-reported outcomes (PROs) in adults with CHD. Methods: After a two year design process, the CHI was created and launched nationally on December 7, 2020 using a human centered design approach. Demographics and validated survey tools on quality of life, mental health, physical activity and health care utilization were collected at baseline and every 4 months. Data were collected virtually and stored on Health Insurance Portability and Accountability Act (HIPAA)–compliant cloud-based servers with restricted access. Results: By December 31, 2023, the CHI had enrolled 4558 participants (56% female) with an average age of 39 years ± 14, representing all 50 states. Approximately 88% of participants have completed at least one e-Visit as of December 31, 2023. The most prevalent CHD anatomy included tetralogy of Fallot (883, 22%), transposition of great arteries (452, 11%), and coarctation of the aorta (429, 11%). Approximately 88% of participants reported at least one co-morbidity, with arrhythmia (1310, 29%) and mood disorder (1339, 29%) as the most common cardiac and non-cardiac co-morbidity, respectively. Among female participants, 45% (n=1147) reported having had a pregnancy with 38% (n=967) resulting in biological children. Participants with complex CHD were less likely to meet recommended physical activity guidelines (X 2 (2, n = 917) = 15.9, p < 0.001), a factor that was more pronounced amongst female participants. Overall health-related quality of life was rated as good or better by 84% of participants with no difference by CHD complexity. Conclusion: CHI is the largest ongoing registry of adults living with congenital heart disease in the US and includes patients with a wide variety of CHD subtypes. Many patients report mood disorders, but most report good or very good health-reported quality of life. The CHI is poised to facilitate multicenter research with the goal of improving clinical outcomes for all adults with CHD.

  • Open Access

    Considerations for Gender‐Affirming Hormonal and Surgical Care Among Transgender and Gender Diverse Adolescents and Adults With Congenital Heart Disease

    by David J. Harrison, Francisco Prada, Natalie J. Nokoff, Sean J. Iwamoto, Tony Pastor, Roni M. Jacobsen, Elizabeth Yeung

    Background: Transgender and gender diverse (TGD) individuals and long‐term survivors with adult congenital heart disease (ACHD) are both growing populations with specialized needs. No studies assess temporal trends or evaluate the care of TGD individuals with ACHD. Methods and Results: Meetings between congenital cardiology and gender‐affirming care specialists identified unique considerations in TGD individuals with ACHD. A retrospective chart review was then performed to describe patient factors and outpatient trends in those with an ACHD diagnosis undergoing gender‐affirming hormonal or surgical care (GAHT/S) at 1 adult and 1 pediatric tertiary care center. Thirty‐three TGD individuals with ACHD were identified, 21 with a history of GAHT/S. Fourteen (66%) had moderate or complex ACHD, 8 (38%) identified as transgender male, 9 (43%) transgender female, and 4 (19%) other gender identities. Three had undergone gender‐affirming surgery. There were zero occurrences of the composite end point of unplanned hospitalization or thrombotic event over 71.1 person‐years of gender‐affirming care. Median age at first gender‐affirming appointment was 16.8 years [interquartile range 14.8–21.5]. The most common treatment modification was changing estradiol administration from oral to transdermal to reduce thrombotic risk (n=3). An increasing trend was observed from zero TGD patients with ACHD attending a gender diversity appointment in 2012 to 14 patients in 2022. Conclusions: There is a growing population of TGD patients with ACHD and unique medical and psychosocial needs. Future studies must fully evaluate the reassuring safety profile observed in this small cohort. We share 10 actionable care considerations for providers with a goal of overseeing a safe and fulfilling gender transition across all TGD patients with ACHD.


  • Pilot Project: Heart Chargers—A Successful Model for a Home-Based Physical Activity Program Utilizing Telemedicine for Fontan Patients

    by Julie C. Fernie, Lisette Wylie, Michal Schäfer, Kara Carnegie, Shelley D. Miyamoto, Roni M. Jacobsen

    Fontan patients have decreased exercise capacity which further declines throughout adolescence. A positive exercise capacity trajectory in children predicts better adult Fontan outcomes. Hospital-based physical activity programs improve exercise capacity and attenuate the age-expected decline in Fontan patients. The purpose of this project was to investigate the feasibility and safety of a partially reimbursable 12-month, home-based, individualized physical activity program (Heart Chargers) for Fontan patients utilizing telemedicine. The Heart Chargers team included a cardiologist, nurse coordinator, and exercise physiologists. Eligible participants with a Fontan completed a baseline cardiopulmonary exercise test (CPET) and consented to participate in Heart Chargers, a 12-month home-based exercise prescription. The individualized exercise prescription focused on skeletal and respiratory muscle strength training and aerobic activities. Participants received a Garmin© device to monitor adherence. Telephone check-ins ranged from weekly to monthly as participants gained independence. Pre- and post-program CPET and informal surveys of physical activity self-efficacy were completed. Nine participants have completed the Heart Chargers program. There was no pre-post difference in maximal or submaximal oxygen consumption (VO2), peak heart rate, or oxygen saturation. There was a significant pre-post increase in systolic blood pressure (p-value 0.004) and minute ventilation (p-value 0.012) at peak exercise. Per subjective report, exercise-related self-efficacy increased after program completion. There were no adverse events. At present, 7 participants remain actively enrolled in the program. Heart Chargers, a novel, home-based, partially reimbursable, 12-month individualized exercise program using telemedicine was successfully implemented in Fontan patients with no adverse events. The lack of decline in exercise capacity for participants is encouraging.


  • Important Considerations in Pediatric Heart Failure

    by J. Blake Wall, Anastacia M. Garcia, Roni M. Jacobsen, Shelley D. Miyamoto

    Purpose of Review The goal of this paper is to provide an overview of contemporary knowledge specific to the causes, management, and outcome of heart failure in children. Recent Findings While recently there have been subtle improvements in heart failure outcomes in children, these improvements lag significantly behind that of adults. There is a growing body of literature suggesting that pediatric heart failure is a unique disease process with age- and disease-specific myocardial adaptations. In addition, the heterogenous etiologies of heart failure in children contribute to differential response to therapies and challenge the ability to obtain meaningful results from prospective clinical trials. Summary Consideration of novel clinical trial designs with achievable but clinically relevant endpoints and focused study of the mechanisms underlying pediatric heart failure secondary to cardiomyopathies and structural heart disease are essential if we hope to advance care and identify targeted and effective therapies.